Osilodrostat

Osilodrostat, sold under the brand name Isturisa, is a medication used for the treatment of adults with Cushing's disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Osilodrostat is an orally active (taken by mouth), nonsteroidal corticosteroid biosynthesis inhibitor which was developed by Novartis for the treatment of Cushing's syndrome and pituitary ACTH hypersecretion (a specific subtype of Cushing's syndrome). It specifically acts as a potent and selective inhibitor of 11β-hydroxylase (CYP11B1).
The most common side effects are adrenal insufficiency, headache, vomiting, nausea, fatigue, and edema (swelling caused by fluid retention). Hypocortisolism (low cortisol levels), QTc prolongation (a heart rhythm condition) and elevations in adrenal hormone precursors (inactive substance converted into a hormone) and androgens (hormone that regulates male characteristics) may also occur in people taking osilodrostat. Osilodrostat was approved for medical use in the European Union in January 2020, and for medical use in the United States in March 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Wikipedia contributors, "Osilodrostat", Wikipedia, revision 1352441253, retrieved 20 November 2026, source, CC BY-SA 4.0.